Free tool
FAERS Monitor: Nplate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125268 or its brand name (Nplate, Romiplostim). Reports on generic versions are filed under their own applications.
Reports
15,183
Serious
11,695
77% of reports
Hospitalization
3,943
Death reported
2,656
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- platelet count decreased1,778
- drug ineffective1,768
- off label use1,282
- thrombocytopenia1,048
- death1,016
- platelet count abnormal962
- therapeutic response decreased942
- headache616
- fatigue478
- platelet count increased404
- hospitalisation393
- haemorrhage391
- arthralgia357
- nausea351
- product storage error345
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 47 |
| 2009 | 410 |
| 2010 | 1,850 |
| 2011 | 2,054 |
| 2012 | 891 |
| 2013 | 527 |
| 2014 | 630 |
| 2015 | 799 |
| 2016 | 616 |
| 2017 | 982 |
| 2018 | 1,124 |
| 2019 | 612 |
| 2020 | 522 |
| 2021 | 536 |
| 2022 | 605 |
| 2023 | 826 |
| 2024 | 790 |
| 2025 | 687 |
| 2026 | 675 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,976 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| platelet count abnormalSignal | 962 | 261.9 | 245.0 | 210,155 |
| platelet count increasedSignal | 404 | 44.3 | 40.1 | 16,526 |
| platelet count decreasedSignal | 1,778 | 23.5 | 22.5 | 37,805 |
| therapeutic response decreasedSignal | 942 | 21.8 | 20.5 | 18,481 |
| thrombocytopeniaSignal | 1,048 | 13.1 | 12.3 | 11,649 |
| product storage errorSignal | 345 | 5.5 | 4.9 | 1,258 |
| haemorrhageSignal | 391 | 5.2 | 4.7 | 1,323 |
| hospitalisationSignal | 393 | 3.5 | 3.2 | 721 |
| off label useSignal | 1,282 | 2.0 | 1.9 | 697 |
| drug ineffective | 1,768 | 1.9 | 1.8 | 747 |
| death | 1,016 | 1.6 | 1.5 | 260 |
| headache | 616 | 1.4 | 1.3 | 60 |
| arthralgia | 357 | 1.2 | 1.1 | 11 |
| fatigue | 478 | 0.9 | 0.8 | 13 |
| nausea | 351 | 0.6 | 0.6 | 88 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.